Clinicopathological Significance of Reduced SPARCL1 Expression in Human Breast Cancer |
Cao, Fang
(Department of Surgery, the Affiliated Kunshan First People's Hospital, Jiangsu University)
Wang, Kuo (Department of Surgery, the Affiliated Kunshan First People's Hospital, Jiangsu University) Zhu, Rong (Department of Surgery, the Affiliated Kunshan First People's Hospital, Jiangsu University) Hu, Yong-Wei (Department of Surgery, the Affiliated Kunshan First People's Hospital, Jiangsu University) Fang, Wen-Zheng (Department of Oncology Fuzhou General Hospital of Nanjing Command) Ding, Hou-Zhong (Department of Surgery, the Affiliated Kunshan First People's Hospital, Jiangsu University) |
1 | Rosman DS, Kaklamani V, Pasche B (2007). New insights into breast cancer genetics and impact on patient management. Curr Treat Options Oncol, 8, 61-73. DOI ScienceOn |
2 | Russo J, Calaf G, Sohi N, et al (1993). Critical steps in breast carcinogenesis. Ann N Y Acad Sci, 698, 1-20. DOI |
3 | Shen FR, Liu M, Zhang X, et al (2012). Health-related quality of life among breast cancer patients and its Influencing Factor in a Chinese Population. Asian Pac J Cancer Prev, 13, 3747-50. DOI ScienceOn |
4 | St Croix B, Rago C, Velculescu V, et al (2000). Genes expressed in human tumor endothelium. Science, 289, 1197-202. DOI ScienceOn |
5 | Sullivan MM, Sage EH (2004). Hevin/SC1, a matricellular glycoprotein and potential tumor-suppressor of the SPARC/BM-40/Osteonectin family. Int J Biochem Cell Biol, 36, 991-6. DOI ScienceOn |
6 | Zhang H, Widegren E, Wang DW, Sun XF (2011). SPARCL1: a potential molecule associated with tumor diagnosis, progression and prognosis of colorectal cancer. Tumour Biol, 32, 1225-31. DOI ScienceOn |
7 | Zaravinos A, Lambrou GI, Boulalas I, Delakas D, Spandidos DA (2011). Identification of common differentially expressed genes in urinary bladder cancer. PLoS One, 6, e18135. DOI ScienceOn |
8 | Isler SG, Schenk S, Bendik I, et al (2001). Genomic organization and chromosomal mapping of SPARC-like 1, a gene down regulated in cancers. Int J Oncol, 18, 521-6. |
9 | Jemal A, Bray F, Center MM, et al (2011). Global cancer statistics. CA Cancer J Clin, 61, 69-90. DOI |
10 | Kallioniemi OP, Wagner U, Kononen J, Sauter G (2001). Tissue microarray technology for high-throughput molecular profiling of cancer. Hum Mol Genet, 10, 657-62. DOI ScienceOn |
11 | Kataja V, Castiglione M, ESMO Guidelines Working Group (2008). Locally recurrent or metastatic breast cancer: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann Oncol, 19, ii11-3. DOI |
12 | Kononen J, Bubendorf L, Kallioniemi A, et al (1998). Tissue microarrays for high-throughput molecular profiling of tumor specimens. Nat Med, 4, 844-7. DOI ScienceOn |
13 | Lau CP, Poon RT, Cheung ST, Yu WC, Fan ST (2006). SPARC and Hevin expression correlate with tumour angiogenesis in hepatocellular carcinoma. J Pathol, 210, 459-68. DOI ScienceOn |
14 | Li P, Qian J, Yu G, et al (2012). Down-regulated SPARCL1 is associated with clinical significance in human gastric cancer. J Surg Oncol, 105, 31-7. DOI ScienceOn |
15 | Long N, Moore MA, Chen W, et al (2010). Cancer epidemiology and control in north-East Asia - past, present and future. Asian Pac J Cancer Prev, 11 suppl 2, 107-48. |
16 | Mencalha AL, Levinsphul A, Deterling LC, Pizzatti L, Abdelhay E (2008). SPARC-like1 mRNA is overexpressed in human uterine leiomyoma. Mol Med Report, 1, 571-4. |
17 | Nelson PS, Plymate SR, Wang K, et al (1998). Hevin, an antiadhesive extracellular matrix protein, is down-regulated in metastatic prostate adenocarcinoma. Cancer Res, 58, 232-6. |
18 | Bendik I, Schraml P, Ludwig CU (1998). Characterization of MAST9/Hevin, a SPARC-like protein, that is downregulated in non-small cell lung cancer. Cancer Res, 58, 626-9. |
19 | Claeskens A, Ongenae N, Neefs JM, et al (2000). Hevin is down-regulated in many cancers and is a negative regulator of cell growth and proliferation. Br J Cancer, 82, 1123-30. DOI ScienceOn |
20 | Eheman C, Henley SJ, Ballard-Barbash R, et al (2012). Annual Report to the Nation on the status of cancer, 1975-2008, featuring cancers associated with excess weight and lack of sufficient physical activity. Cancer, 118, 2338-66. DOI ScienceOn |
21 | Esposito I, Kayed H, Keleg S, et al (2007). Tumor-suppressor function of SPARC-like protein 1/Hevin in pancreatic cancer. Neoplasia, 9, 8-17. DOI |
22 | Hu H, Zhang H, Ge W, et al (2012). Secreted protein acidic and rich in cysteines-like 1 suppresses aggressiveness and predicts better survival in colorectal cancers. Clin Cancer Res, 18, 5438-48. DOI ScienceOn |
23 | Girard JP, Springer TA (1995). Cloning from purified high endothelial venule cells of hevin, a close relative of the antiadhesive extracellular matrix protein SPARC. Immunity, 2, 113-23. DOI ScienceOn |
24 | Girard JP, Springer TA (1996). Modulation of endothelial cell adhesion by hevin, an acidic protein associated with high endothelial venules. J Biol Chem, 271, 4511-7. DOI |
25 | Hambrock HO, Nitsche DP, Hansen U, et al (2003). SC1/hevin. An extracellular calcium-modulated protein that binds collagen I. J Biol Chem, 278, 11351-8. DOI ScienceOn |
26 | Hulvat MC, Hansen NM, Jeruss JS (2009). Multidisciplinary care for patients with breast cancer. Surg Clin North Am, 89, 133-76, ix. DOI ScienceOn |
27 | Hurley PJ, Marchionni L, Simons BW, et al (2012). Secreted protein, acidic and rich in cysteine-like 1 (SPARCL1) is down regulated in aggressive prostate cancers and is prognostic for poor clinical outcome. Proc Natl Acad Sci USA, 109, 14977-82. DOI |
28 | Isler SG, Ludwig CU, Chiquet-Ehrismann R, Schenk S (2004). Evidence for transcriptional repression of SPARC-like 1, a gene downregulated in human lung tumors. Int J Oncol, 25, 1073-9. |